Heritage Trust Co bought a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) in the 3rd quarter, HoldingsChannel reports. The fund bought 1,660 shares of the medical research company’s stock, valued at approximately $1,121,000.
A number of other hedge funds also recently made changes to their positions in TMO. White Pine Capital LLC purchased a new position in Thermo Fisher Scientific in the third quarter valued at approximately $703,000. Cornerstone Advisors LLC raised its stake in Thermo Fisher Scientific by 121.9% in the 3rd quarter. Cornerstone Advisors LLC now owns 28,646 shares of the medical research company’s stock valued at $19,337,000 after acquiring an additional 15,734 shares during the period. Russell Investments Group Ltd. raised its position in shares of Thermo Fisher Scientific by 3.9% in the third quarter. Russell Investments Group Ltd. now owns 351,042 shares of the medical research company’s stock valued at $237,133,000 after purchasing an additional 13,133 shares during the period. Allspring Global Investments Holdings LLC lifted its position in shares of Thermo Fisher Scientific by 9.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 140,228 shares of the medical research company’s stock worth $91,500,000 after acquiring an additional 12,414 shares in the last quarter. Finally, Leelyn Smith LLC lifted its holdings in Thermo Fisher Scientific by 0.8% during the 3rd quarter. Leelyn Smith LLC now owns 9,789 shares of the medical research company’s stock worth $6,608,000 after purchasing an additional 77 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
Several research firms have issued reports on TMO. Wells Fargo & Company cut shares of Thermo Fisher Scientific from an “overweight” rating to an “underweight” rating in a research note on Wednesday, September 9th. TD Cowen boosted their price target on shares of Thermo Fisher Scientific from $760.00 to $810.00 and gave the company a “buy” rating in a research report on Thursday, October 22nd. Piper Sandler started coverage on shares of Thermo Fisher Scientific in a report on Wednesday, September 9th. They issued an “overweight” rating and a $510.00 price target on the stock. Barclays lifted their price objective on Thermo Fisher Scientific from $750.00 to $775.00 and gave the company an “overweight” rating in a research note on Thursday, October 22nd. Finally, CLSA began coverage on Thermo Fisher Scientific in a research report on Thursday, September 3rd. They set an “outperform” rating and a C$748.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $683.64.
View Our Latest Stock Analysis on Thermo Fisher Scientific
Insiders Place Their Bets
In other news, VP Lisa P. Britt sold 11,440 shares of the company’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total value of $7,014,092.80. Following the completion of the transaction, the vice president directly owned 14,784 shares in the company, valued at approximately $9,064,366.08. This represents a 43.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $629.27, for a total value of $6,292,700.00. Following the transaction, the chief executive officer owned 123,925 shares in the company, valued at $77,982,284.75. This trade represents a 7.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 24,546 shares of company stock worth $15,479,192. 0.33% of the stock is owned by insiders.
Thermo Fisher Scientific Trading Down 1.2%
Shares of Thermo Fisher Scientific stock opened at $691.56 on Tuesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.81 and a quick ratio of 1.41. Thermo Fisher Scientific Inc. has a 1 year low of $435.27 and a 1 year high of $727.56. The firm has a market cap of $256.24 billion, a PE ratio of 36.47, a PEG ratio of 2.85 and a beta of 0.84. The company has a 50 day simple moving average of $672.40 and a two-hundred day simple moving average of $557.23.
Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last issued its quarterly earnings results on Wednesday, October 21st. The medical research company reported $6.68 EPS for the quarter, topping analysts’ consensus estimates of $6.40 by $0.28. The firm had revenue of $12.14 billion for the quarter, compared to analyst estimates of $11.95 billion. Thermo Fisher Scientific had a net margin of 14.94% and a return on equity of 17.33%. The business’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $5.79 EPS. Analysts expect that Thermo Fisher Scientific Inc. will post 25.26 earnings per share for the current fiscal year.
Thermo Fisher Scientific Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Friday, January 15th. Investors of record on Tuesday, December 15th will be given a $0.47 dividend. The ex-dividend date is Tuesday, December 15th. This represents a $1.88 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s payout ratio is 9.92%.
About Thermo Fisher Scientific
Thermo Fisher Scientific develops and supplies products and services used in scientific research, clinical diagnostics, and pharmaceutical and biotechnology manufacturing. Its offerings include laboratory instruments, reagents and consumables, analytical equipment, diagnostic tests, and services that support drug development and clinical research. The company operates through businesses focused on life sciences, analytical instruments, specialty diagnostics, and laboratory products and biopharma services.
Read More
- Five stocks we like better than Thermo Fisher Scientific
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
